Bunnage Mark E. sold VRTX
February 25, 2026 · Form 4 insider transaction
Bunnage Mark E. sold 620 shares of Vertex Pharmaceuticals Incorporated at $486.35 per share, a transaction worth $301.5K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Disposed (sell-side)
Shares
620
Price
$486.35
Total value
$301.5K
InsiderBunnage Mark E.
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateFebruary 25, 2026
Filing dateFebruary 26, 2026
Shares owned after7,284
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.